Tuesday - May 6, 2025

LOGIN  |  REGISTER
Assertio
Viking Therapeutics

Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2025 Results: May 8, 2025

March 31, 2025 | Last Trade: US$62.49 1.36 -2.13

BOSTON, March 31, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter and fiscal year 2025 financial results at 6:00 am ET on Thursday, May 8, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 8, 2025.

The call can be accessed via teleconference at: Q4 2025 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.

A live webcast of the call can be accessed on Haemonetics' investor relations website. Webcast Link: https://edge.media-server.com/mmc/p/4z9yixt9 

A replay of the conference call and webcast will be available for one year beginning on May 8, 2025 at 11:00 am ET using the conference call webcast link provided in this press release.

ABOUT HAEMONETICS

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.

Investor Contacts:

 

Olga Guyette, Vice President-Investor Relations & Treasury

David Trenk, Manager-Investor Relations

(781) 356-9763

(203) 733-4987

olga.guyette@haemonetics.com

david.trenk@haemonetics.com 

  

Media Contact:

 

Josh Gitelson, Sr. Director-Global Communications

 

(781) 356-9776

 

josh.gitelson@haemonetics.com

 
Terns Pharmaceuticals

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page